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Abstract: Nonviral gene and small interfering RNA (siRNA) delivery formulations are 
extensively used for biological and therapeutic research in cell culture experiments, but less so 
in in vivo and clinical research. Difficulties with formulating the nanoparticles for uniformity 
and stability at concentrations required for in vivo and clinical use are limiting their progression 
in these areas. Here, we report a simple but effective method of formulating monodisperse 
nanocomplexes from a ternary formulation of lipids, targeting peptides, and nucleic acids at 
a low starting concentration of 0.2 mg/mL of DNA, and we then increase their concentration up 
to 4.5 mg/mL by reverse dialysis against a concentrated polymer solution at room temperature. 
The nanocomplexes did not aggregate and they had maintained their biophysical properties, 
but, importantly, they also mediated DNA transfection and siRNA silencing in cultured cells. 
Moreover, concentrated anionic nanocomplexes administered by convection-enhanced deliv-
ery in the striatum showed efficient silencing of the β-secretase gene BACE1. This method of 
preparing nanocomplexes could probably be used to concentrate other nonviral formulations 
and may enable more widespread use of nanoparticles in vivo.
Keywords: nanoparticles, concentration, anionic liposome, siRNA, DNA, targeted gene 
delivery
Introduction
Nonviral formulations comprising mixtures of cationic polymers or lipids that self-
assemble into nanoparticles upon mixing with nucleic acids have been widely used in 
genetic and gene therapy research since the late 1980s. More recently, these vectors 
have become more prevalent with the development of small interfering RNA (siRNA)-
mediated gene silencing.1–8 While a wide variety of formulations are used in cell culture 
experiments, the number of formulations in clinical trials for gene or siRNA therapies 
is more limited.8 The barriers to transfection in vivo8,9 are very different to the cell cul-
ture environment and not all formulations are compatible with usage in live animals. 
A further challenge is the technical problems associated with preparing monodisperse 
nanoparticle formulations in the volumes and concentrations required in vivo.10
Self-assembly of nanoparticles with cationic reagents and nucleic acids is mediated 
largely by electrostatic interactions. Empirically optimized ratios of these components 
are required to produce monodisperse nanoparticles with peak transfection efficiency. 
The formulation used in this study comprises a mixture of liposomes and targeting 
peptides that self-assemble on mixing with DNA11–18 or siRNA19–21 to form LPD or LPR 
receptor-targeted nanocomplexes (RTNs). Based on this platform, we have described 
both cationic and anionic RTN formulations and shown their in vivo potential by delivery 
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to tumors, lung epithelium, brain, and blood vessels.11–16,18,21,22 
The formulation of RTNs is more complicated than simple 
lipoplex or polyplexes and becomes increasingly problematic 
in our experience at higher nucleic acid concentrations of 
more than 0.5 mg/mL with large aggregates and precipitates 
forming, which leads to poor biodistribution, systemic toxic-
ity, and low transfection efficiency in vivo.10
The RTN formulation process requires fast mixing of 
liposome, peptide, and nucleic acid components, which 
is easily achieved by rapid pipetting at low volumes and 
concentrations – for example, where the nucleic acid is less 
than 300 μg/mL. For in vivo applications by systemic deliv-
ery, or in the brain where only very small volumes can be 
injected, higher concentrations of nucleic acids are required 
of 1 mg/mL or more.10,23 At these concentrations, nano-
complexes following pipette-based mixing methods, even 
in small volumes, rapidly precipitate due to instantaneous 
electrostatic interactions of the components. Sophisticated 
mixing technologies are available such as microfluidics, 
continuous flow systems, and in-line mixing,24–27 but each 
of these usually requires expensive equipment and time-
consuming optimization of the process and consumes large 
amounts of materials increasing costs.
Recently, Vauthier et al28 proposed a method of concen-
trating nanoparticles without aggregation using osmosis in 
a simple laboratory setup. We report here the application of 
this facile, small-scale method to concentrate LPD and LPR 
formulations, which should work equally well with liposomal 
or polymeric nanocomplex formulations, enhancing their util-
ity for in vivo experiments. Nanocomplexes were evaluated 
for their biophysical properties, as well as for their in vitro 
and in vivo transfection efficiencies. This method could find 
widespread utility in the development of many different 
nucleic acid formulations for in vivo applications, potentially 
hastening the development of new genetic therapies.
Materials and methods
Materials
Dextran (molecular weight [MW] 150,000) from Leuconostoc 
mesenteroides and dialysis tubing cellulose mem-
brane MW cut-off (CO) 14,000 were obtained from 
Sigma-Aldrich Co. (St Louis, MO, USA). 1,2-dioleoyl-
sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 1,2-di-
O-octadecenyl-3-trimethylammonium propane (DOTMA), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
(methoxy[polyethylene glycol]-2000) (DPPE PEG2000), 
and DOTMA/DOPE (1:1 molar ratio) were purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Peptide Y 
(K
16
GACYGLPHKFCG) was synthesized by ChinaPep-
tides Co., Ltd. (Shanghai, People’s Republic of China). 
Rabies virus glycoprotein targeting peptide (RVG-9R) 
(YTIWMPENPRPGTPCDIFTNSRGKRASNGGGG-
RRRRRRRRR) was synthesized by AMS Biotechnology 
Limited (Abingdon, UK). Silencer Firefly Luciferase 
(GL2 + GL3) and Silencer Negative Control #1 siRNA 
were obtained from Applied Biosystems (Thermo Fisher 
Scientific, Waltham, MA, USA). Lipofectamine® 2000 (L2K) 
was purchased from Invitrogen (Thermo Fisher Scientific). 
The siRNA for the BACE1 in vivo studies was bought from 
Eurofins MWG Operon LLC (Huntsville, AL, USA) and the 
sequences were: BACE1 (sense) 5′ GCUUUGUGGAGAUG-
GUGGAdTdT 3′; and BACE1 (antisense) 5′ UCCACCAU-
CUCCACAAAGCdTdT 3′. The plasmid pCI-Luc consists 
of the luciferase gene from pGL3 (Thermo Fisher Scientific) 
subcloned into pCI (Promega Corporation, Fitchburg, WI, 
USA). The plasmid pEGFP-N1 (4.7 kb) containing the 
gene GFP was obtained from Clontech Laboratories, Inc. 
(Mountain View, CA, USA).
liposome and nanoparticle formulation
Lipid stocks were dissolved in chloroform at 10 mg/mL. 
Lipids were then mixed at the required molar ratios in 
a round-bottomed flask and the chloroform was slowly 
evaporated in a rotary evaporator (BÜCHI Labortechnik 
AG, Flawil, Switzerland) to produce a lipid film. Lipids 
were then rehydrated with sterile, distilled water while con-
stantly rotated overnight, and they were then sonicated in 
an ultrasonic water bath (Jencons-PLS, Bedfordshire, UK) 
to reduce their size. The anionic liposomes that were 
made were: DOPG:DOPE:DOPE PEG2000 (LAP1); and 
DOPG:DOPE:DPPE PEG2000 (LAP2) at a molar ratio of 
47.5:47.5:5 mol%, respectively.16,21
Anionic nanocomplexes were prepared in water at a 
4:3:1 molar charge ratio16 of liposome:peptide:siRNA or 
liposome:peptide:DNA, by adding the peptide to the siRNA 
(PRL) or DNA (PDL), incubating for 15 minutes at room 
temperature, and then adding the liposome with rapid mixing 
and incubating at room temperature for a further 20 min-
utes. Cationic RTN formulations (at a weight ratio of 1:4:1, 
liposome:peptide:DNA) were made by first adding the pep-
tide to the liposome DOTMA/DOPE, followed by addition of 
the DNA with rapid mixing and incubation for 30 minutes at 
room temperature to allow for complex formation. The nano-
complexes prepared were termed LYD (liposome DOTMA/
DOPE, peptide Y, and DNA), PRL (peptide Y or RVG-9R, 
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siRNA, liposome LAP2), and PDL (peptide Y, DNA, liposome 
LAP1). Peptide/siRNA nanocomplexes were also made by 
mixing peptide RVG-9R with siRNA at a 4:1 weight ratio 
and incubation at room temperature for 30 minutes.
Concentration experiments by reverse 
dialysis
The dialysis tubing was boiled in a solution of 2% 
NaHCO
3
/1 mM ethylenediaminetetraacetic acid (EDTA) 
for 10 minutes. It was then rinsed thoroughly with ddH
2
O 
and then boiled for 10 minutes in a solution of 1 mM EDTA. 
It was then rinsed with ddH
2
O, cooled at room temperature, 
and then stored at 4°C in a fresh solution of 1 mM EDTA. 
Dextran solutions (100–300 g/L) were prepared by dissolv-
ing small amounts of dextran in sterile ddH20 by stirring and 
heating at 60°C for 30 minutes.
Then, 0.5–1.5 mL of nanocomplexes were prepared 
as described earlier at a nucleic acid concentration of 
175–200 μg/mL. The volume of the counter-dialysis 
(dextran) medium was 12–14 mL (depending on the volume 
of the nanocomplexes in the tubing), and different concen-
trations of dextran were used: 100 g/L; 150 g/L; 200 g/L; 
250 g/L; and 300 g/L. Dialysis was performed at room 
temperature in disposable conical centrifuge 15 mL tubes. 
At different time points, and at the end of the dialysis, the 
concentrated nanocomplexes were collected from the dialysis 
tubing and the concentration was measured in a NanoDrop 
spectrophotometer (Thermo Fisher Scientific), and the 
size and charge measurements were performed, as will be 
described. Each experiment was performed in triplicate.
Particle size and charge measurements
Nanocomplex preparations were diluted with distilled water 
to a final volume of 1 mL at a concentration of 5 μg/mL with 
respect to DNA or siRNA. They were then analyzed for size 
by intensity and charge (ζ potential) by dynamic light scat-
tering (DLS) using a Malvern Nano ZS Zetasizer (Malvern 
Instruments, Malvern, UK). The data were then processed by 
software provided by the manufacturer, DTS version 5.03. 
Size measurements with a polydispersity index (PDI) of less 
than 0.3 were accepted as monodisperse.
In vitro transfections
The murine neuroblastoma cell line Neuro-2A (American 
Type Culture Collection, Manassas, VA, USA) and Neuro-
2A-Luc cells, were maintained in Dulbecco’s Modified 
Eagle’s Medium, 1% nonessential amino acids, 1 mM 
sodium pyruvate, and 10% fetal calf serum (FCS) (Thermo 
Fisher Scientific). The human bronchial epithelial cells 
16HBE14o− (shortened to HBE) were provided by 
D Gruenert (San Francisco, CA, USA) and were cultured in 
Eagle’s Minimal Essential Medium with HEPES modifica-
tion (Sigma-Aldrich Co.), 10% FCS, and 2 mM L-glutamine. 
All cells were maintained at 37°C in a humidified atmosphere 
in 5% carbon dioxide. Cells were seeded in 96-well plates at 
2×104 cells per well 24 hours prior to transfection. Following 
the removal of growth medium, 200 μL of complexes that 
underwent concentration were diluted in OptiMEM in order 
to contain 0.25 μg of plasmid DNA or 50 nM siRNA, and they 
were added to the cells in replicates of six. The same amount of 
DNA or siRNA was added per well when the nanocomplexes 
were made fresh (ie, not concentrated). Plates were centri-
fuged at 1,500 rpm for 5 minutes (400× g) and incubated for 
4 hours at 37°C, then transfection medium was replaced by 
the complete growth medium and incubated for a further 
24 hours. Luciferase expression was measured in cell lysates 
with a luciferase assay (Promega Corporation) in a FLUOstar 
OPTIMA luminometer (BMG LABTECH GmbH, Ortenberg, 
Germany). The amount of protein present in each sample 
was determined with the Bio-Rad protein assay reagent (Bio-
Rad Laboratories Inc., Hercules, CA, USA) in a FLUOstar 
OPTIMA luminometer. Luciferase activity was expressed 
as relative light units per milligram of protein (RLU/mg). 
Each measurement was performed in groups of six and the 
mean was determined.
Neuro-2A cells were seeded in 96-well plates at 1.2×104 
cells per well 24 hours prior to transfection with 175 μL 
of complete serum-containing media. Twenty-four hours 
later, 25 μL of concentrated PDL complexes were diluted 
in OptiMEM to contain 0.25 μg of green fluorescent protein 
(GFP) plasmid DNA and then added to the cells in replicates 
of six. Plates were centrifuged at 1,500 rpm for 5 minutes 
(400× g) and incubated for 48 hours at 37°C. They were 
then imaged (20× magnification) using an Olympus IX70 
fluorescent microscope (Olympus Corporation, Tokyo, 
Japan).
Transmission electron microscopy (TEM)
Copper grids (300-mesh) coated with a Formvar/carbon 
support film (Agar Scientific Ltd, Stansted, UK) were 
prepared by glow discharge in an Emitech K350G system 
(Emitech LTD, Nicosia, Cyprus). Nanocomplex preparations 
were applied to grids as a droplet then after 5 seconds, the 
grid was dried by blotting with filter paper. The sample was 
then negatively stained with 1% uranyl acetate for 2–3 sec-
onds, before blotting with filter paper and air-dried. Imaging 
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was performed with a Philips CM120 BioTwin TEM and 
operated at an accelerating voltage of 120 kV. The images 
were captured using an AMT 5 MP digital TEM camera 
(Deben UK Limited, Suffolk, UK).
Cell proliferation assay
Cell viability was assessed using the CellTiter 96® Aqueous 
One Solution Cell Proliferation Assay (Promega Corporation). 
Neuro-2A cells were seeded in 96-well plates and transfected 
with anionic and cationic concentrated nanocomplexes that 
were diluted in OptiMEM, as discussed earlier. After 24 hours, 
the media were changed with growth media containing 20 μL 
of CellTiter 96 Aqueous One Solution reagent. Finally, after 
incubation for 2 hours, absorbance was measured at 490 nm on 
a FLUOstar OPTIMA spectrophotometer (BMG LABTECH 
GmbH). Cell viability for each complex was expressed as a 
percentage of the viability of control cells.
Ex vivo silencing study using RVG-9R 
peptide
Brains were obtained from wild-type CD1 mice and cut into 
small pieces (~2 mm ×2 mm ×2 mm) in a Petri dish under 
sterile conditions, then moved to a 24-well plate by forceps. 
Then, 1 mL of DMEM (1% antibiotics, no serum) was added 
to each well and incubated at 37°C and transfected in trip-
licate, as described previously. Forty-eight hours later, the 
medium was removed from the culture dish and the tissues 
were processed for RNA extraction using the RNeasy kit 
according to the manufacturer’s instructions (Qiagen NV, 
Venlo, the Netherlands).
In vivo procedures
All murine in vivo studies were performed in accordance 
with University College London’s animal care policies 
and with the authority of the appropriate UK Home Office 
licenses. CD1 female mice (6–8 weeks old) were injected 
intravenously with 100 μL of anionic PRL nanoparticles 
(with peptide RVG-9R) containing 16 μg or 50 μg of siRNA 
(0.64–2 mg/kg) in 5% dextrose. Mice were euthanized 
48 hours later and their brains were placed in RN Alater 
(Thermo Fisher Scientific). All rat in vivo studies were per-
formed in accordance with the University of Bristol’s animal 
care policies and with the authority of the appropriate UK 
Home Office licenses. Adult male Wistar rats (Charles River 
Laboratories International, Inc., Wilmington, MA, USA) 
(225–275 g) were used for convection-enhanced delivery 
(CED), as described previously.15,21 A total volume of 5 μL 
(6 μg of siRNA or 0.024 mg/kg) of anionic PRL nanoparticles 
(with peptide RVG-9R) in 5% dextrose was delivered to 
the striatum at an infusion rate of 2.5 μL/minute. Rats were 
euthanized 48 hours later, and the striata were placed in 
RNAlater (Thermo Fisher Scientific).
qRT-PCR
Total RNA was extracted from rat brain using the RNeasy 
kit according to the manufacturer’s instructions (Qiagen 
NV). RNA was checked for integrity using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
All RNA samples had an RNA integrity number of more than 
8, indicating high-quality RNA. Prior to reverse transcrip-
tion, each RNA sample was treated with DNase (Thermo 
Fisher Scientific). First-strand complementary DNA was 
synthesized from 1 μg of DNase-treated RNA, using random 
hexamers, and Superscript II reverse transcriptase (Thermo 
Fisher Scientific) in a 1-hour reaction at 37°C. Rat BACE1 
and rat beta-actin complementary DNAs were then quantified 
using Taqman primers and probes (Rn00569988_m1 and 
Rn00667869_m1, respectively; Thermo Fisher Scientific) 
and an ABI PRISM® 7000 Sequence Detection System 
(Applied Biosystems; Thermo Fisher Scientific). The quanti-
tative reverse transcription polymerase chain reaction (qRT-
PCR) assay conditions were: stage 1, 50°C for 2 minutes; 
stage 2, 95°C for 10 minutes; stage 3, 95°C for 15 seconds, 
then 60°C for 1 minute; repeated 40 times.
Western blot
Protein gel electrophoresis and Western blot analysis were 
performed as described previously.21 Briefly, total pro-
tein was extracted from mouse brain using the Precellys® 
Homo genizer (Stretton Scientific Ltd, Derbyshire, UK). 
Forty micrograms of protein were loaded and separated 
using NuPAGE® Precast gels (10% Bis-Tris; Thermo Fisher 
Scientific) and then transferred electrophoretically to a 
polyvinylidene fluoride membrane (Thermo Fisher Scien-
tific). The primary antibodies used in this study were rabbit 
anti-BACE1 polyclonal antibody (EE-17, 1:1,000; Sigma-
Aldrich Co.) and mouse anti-β-tubulin monoclonal antibody 
(1:5,000; Sigma-Aldrich Co.), and the secondary antibodies 
were a horseradish peroxidase-conjugated antimouse or 
antirabbit immunoglobulin G (Stratech Scientific Ltd, Suf-
folk, UK) (1:50,000). Semiquantification of the bands was 
performed by densitometry using the ImageJ software.
Statistical analysis
The data presented in this study are expressed as the mean ± 
standard deviation and were analyzed using a two-tailed, 
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unpaired Student’s t-test or one-way analysis of variance and 
Bonferroni’s post hoc analysis, where applicable. 
Results and discussion
concentrating nanoparticles and 
biophysical characterization
Concentration of LYD nanoparticles19 by reverse dialysis was 
first performed through cellulose dialysis membrane (MWCO: 
14,000) against solutions of dextran (MW: 150,000) dissolved 
in a range of concentrations. The high osmotic pressure of the 
dextran solutions leads to the displacement of water from the 
tubing into the surrounding dextran solution. Figure 1A shows 
the change in concentration of nanocomplexes achieved 
over time from a starting concentration of 0.2 mg/mL with 
respect to the DNA with varying dextran concentrations. 
The lowest dextran concentration of 100 g/L resulted in a 
30% increase in nanocomplex concentration after 9 hours of 
dialysis, whereas the 150 g/L, 200 g/L, 250 g/L, and 300 g/L 
concentrations resulted in 3.9-fold (in 8.5 hours), 2.7-fold 
(in 9 hours), 8.2-fold (in 6 hours), and 23.9-fold (in 5 hours 
and 15 minutes) increases, respectively. When longer time 
points were assessed for dextran at 100 g/L (24 hours) and 
150 g/L (15 hours and 15 minutes), 2.25-fold and 10.6-fold 
increases in DNA concentration were achieved, respectively. 
At dextran concentrations of 150 g/L nanoparticle concen-
trations of 0.59–4.6 mg/mL were achieved, which is in the 
target range for possible clinical applications.10,29
The effect of the starting volume at three different 
concentrations of dextran (100 g/L, 200 g/L, and 300 g/L) 
was investigated for its effects on the rate of concentration 
increase. Table 1 shows that smaller starting volumes 
were concentrated more quickly. For example, at 300 g/L, 
a ~9-fold concentration of DNA in a 0.5 mL formulation was 
achieved in only 2.2 hours, while 4.5 hours were required for 
the equivalent 1.5 mL formulation (Figure 1A). Therefore, 
the osmotic pressure applied to the nanoparticle solution 
could be controlled through the dextran concentration in the 
counter-dialyzing solution, which significantly affected the 
rate of water transfer between the two compartments.
The sizes and zeta potentials (Figure 1B) of LYD 
nanocomplexes were determined before and after con-
centrating with different dextran solutions (100–300 g/L). 
There was no statistical difference in either the size or the 
zeta potential before and after concentration (size ranges: 
98–137 nm and zeta potential: +64–69 mV), indicating that 
this procedure does not alter these biophysical properties. 
All PDI measurements before and after concentration 
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Figure 1 effect of different concentrations of dextran on concentrating cationic lYD nanoparticles and on size and zeta potential.
Notes: (A) Kinetics of the concentration of LYD nanoparticles over time when varying the concentration of dextran (100–300 g/L). (B) size and charge measurements of 
LYD nanoparticles by dynamic light scattering before and after concentration with different amounts of dextran (100–300 g/L).
Abbreviation: LYD, liposome 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), peptide 
Y, and DNa.
Table 1 starting nanoparticle volumes, dextran concentrations 
used, total time of concentration, and concentration factors 
achieved for lYD formulations
Volume
(mL)
Dextran concentration  
(g/L)
Time  
(hours)
Fold  
concentration
1.5 100 24 2.2
1.0 100 24 2.1
0.5 100 9 2.6
1.5 200 9 2.7
1.0 200 3.75 2.6
0.5 200 3.25 3.2
1.5 300 5.15 23.9
1.0 300 4 20.2
0.5 300 2.2 8.9
Abbreviation: LYD, liposome 1,2-di-O-octadecenyl-3-trimethylammonium propane 
(DOTMA)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), peptide Y, 
and DNa.
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were 0.3, indicating monodisperse nanoparticle populations. 
Cationic (LYD) and anionic (PDL and PRL) nanoparticle 
formulations16,21 were further characterized by negative stain-
ing TEM to determine their shape and morphology before 
and after concentration using 300 g/L of dextran (Figure 2). 
Most nanocomplexes were spheres (Figure 2A–C), but 
/<'VWDUW$
%
&
/<'HQG
3'/VWDUW 3'/HQG
35/VWDUW 35/HQG
Figure 2 Electron microscopy of nanocomplexes.
Notes: Negative staining transmission electron microscopy was used to visualize (A) lYD nanoparticles before and after concentration, (B) PDl nanoparticles before and 
after concentration, and (C) Prl nanoparticles before and after concentration. scale bar =500 nm for all nanoparticles. 300 g/L dextran was used to concentrate all three 
different nanoparticle formulations.
Abbreviations: LYD, liposome 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), peptide Y, and 
DNa; PDl, peptide Y, DNa, liposome laP1; PRL, peptide Y or RVG-9R, siRNA, liposome LaP2.
with some rods (in LYD and PDL; Figure 2A and B) and 
some toroidal structures (Figure 2A and B). The majority 
of the spherical particles measured by TEM for each for-
mulation were in the range determined by DLS with no 
obvious differences between formulations before and after 
concentration.
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This method of concentration has several advantages, 
as it preserves the biophysical characteristics of the 
nanocomplexes, avoids aggregation of the nanoparticles, 
and is a quick and simple method that does not need any 
specialized equipment.28 Based on the efficacy of the 
concentration, the short but predictable time required, and 
the fact that there were no major biophysical changes to the 
nanocomplexes before and after, we decided to use a dextran 
concentration of 300 g/L in ongoing experiments (unless 
otherwise stated).
concentration of lPD nanoparticles 
maintains their functional abilities
LYD nanoparticles were concentrated using different amounts of 
dextran (100–300 g/L), and were then used for the transfection of 
Neuro-2A cells (Figure 3A). There was no statistical difference 
in the transfection efficiency between the formulations irrespec-
tive of the amount of dextran used, or if they were concentrated 
or nonconcentrated. The same was true when the LYD nano-
particles that were concentrated against 300 g/L of dextran were 
used for the transfection of HBE cells (Figure 3B).
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Figure 3 In vitro transfections with concentrated nanocomplexes retain transfection efficiency with lack of cytotoxicity.
Notes: (A) A total of 1.5 mL of LYD nanocomplexes were concentrated using different amounts of dextran (100–300 g/L) and were used in luciferase transfections in 
Neuro-2A cells. (B) lYD nanoparticles before and after concentration (concentrated for 3 hours and 5 hours, 15 minutes) were used in luciferase transfections in hBe cells. 
(C) sirNa silencing from anionic Prl nanocomplexes (with peptide Y) before or after concentration made at a 4:3:1 molar charge ratio using sirNa targeting luciferase 
in Neuro-2A-Luc cells at 50 nM. 24 hours later, luciferase assays were performed. L2K/siRNA nanocomplexes were used as a positive control in all in vitro silencing 
experiments. (D) Viability of Neuro-2A cells following transfection for 24 hours with cationic LYD and anionic PDL and PRL nanocomplexes. Cationic nanocomplexes were 
made at a weight ratio of 1:4:1 (liposome:peptide:DNA) and the anionic nanocomplexes at a molar charge ratio of 4:3:1 (liposome:peptide:siRNA). The viability values were 
normalized to the untransfected control cells. The dextran concentration in the counter-dialyzing solution was kept constant (300 g/L) in Figure 3B–D. All transfections were 
performed in groups of six and mean values were calculated. Asterisks indicate comparisons of specific formulations with statistical significance (**P0.01; ***P0.001).
Abbreviations: RLU, relative light units; LYD, liposome 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPe), peptide Y, and DNa; hBe, human bronchial epithelial cells 16hBe14o−; sirNa, small interfering rNa; sirNa Irr, irrelevant control small interfering 
rNa; l2K, lipofectamine® 2000; PRL, peptide Y or RVG-9R, siRNA, liposome LaP2; conc, concentrated; PDl, peptide Y, DNa, liposome laP1; P, peptides; r, sirNa; 
D, DNa; h, hours.
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The concentrated, anionic PRL nanoparticles (with 
peptide Y)21 were used for luciferase silencing of Neuro- 
2A-Luc cells (Figure 3C). All anionic formulations resulted 
in significant silencing between 45%–70%, and there was 
no difference between concentrated and nonconcentrated 
samples. The cell viability showed no particular difference 
between all the formulations tested, which included cationic 
LYD and anionic PDL and PRL made fresh or following 
concentration (Figure 3D).
The transfection efficiency of an anionic polyethylene 
glycol (PEG)ylated PDL formulation was evaluated with 
the plasmid expressing enhanced GFP in Neuro-2A cells. 
Fluorescent microscopy images provided evidence of the 
high transfection efficiency of PDL anionic nanoparticles 
following concentration (Figure 4).
ex vivo and in vivo administration 
of RVG-containing nanocomplexes
We then evaluated an LPR formulation for brain delivery 
using RVG-9R, which binds the nicotinic acetylcholine 
receptor,30 formulated with anionic liposomes and siRNA 
against the neuronal enzyme beta-secretase (BACE1). This 
enzyme cleaves the amyloid precursor protein to generate 
amyloid-beta peptides, which are landmarks in Alzheimer’s 
disease pathophysiology.31,32 BACE1 is therefore a main 
therapeutic target for Alzheimer’s disease.
Ex vivo silencing studies were first performed with brain 
explant tissue transfected with 100 nM siRNA in anionic PRL 
nanoparticles containing RVG-9R or PR nanoparticles con-
taining RVG-9R and siRNA (RVG-9R/siRNA). The analysis 
of silencing by qRT-PCR revealed about 40% silencing of 
BACE1 with PRL nanoparticles (P0.05) and no silencing 
was achieved with RVG-9R/BACE1R complexes (Figure 5A). 
L2K, which was used as a positive control, achieved 54% 
silencing compared to its irrelevant siRNA control (P0.01). 
Western blotting revealed 32% silencing of BACE1 protein 
(Figure 5B). We then progressed to in vivo studies with just 
RVG-9R-targeted anionic PRL nanoparticles.
PRL nanocomplexes were then prepared for in vivo use 
by formulating initially at a concentration of 0.18 mg/mL 
BACE1 or irrelevant siRNA and then concentrated by dialy-
sis against 300 g/L dextran over 4.5 hours, achieving an over 
sixfold concentration (Figure 5C). These nanoparticles were 
used for all the subsequent in vivo studies in mice and rats. 
The size and charge of concentrated BACE1 siRNA formula-
tions were 79.9±2.95 nm and −44.8±1.5 mV, respectively, 
while the values for irrelevant control siRNA PRLs were 
similar at 73.3±4.0 nm and −36.9±2.3 mV.
Concentrated nanoparticles were administered intrave-
nously into mice, and 48 hours later, the brains were assessed 
for silencing. No silencing of mouse BACE1 was detected 
following intravenous injections (Figure 5D), unlike other 
reports that showed silencing even when the RVG/siRNA 
were delivered by intravenous injections.30,33–35 Other recent 
research showed nanoparticle deposition in the brain, but it 
did not examine the silencing effects there,36 or it assessed 
increased enzymatic activity following β-galactosidase 
administration.37 The lack of silencing following the intra-
venous administration of RVG-containing nanoparticles 
could be due to differences in both the amount of dose and 
the number of doses delivered, as we used a single 16 μg 
or 50 μg dose, whereas others use 50–150 μg for up to four 
doses.30,33–35 In addition, the nanoparticles used here are 
formed by self-assembly, whereas others use conjugation of 
the peptide by covalent bonds on the surface of the delivery 
vectors.36,37 However, this does not imply that our RVG 
Figure 4 GFP transfection efficiency of nanocomplexes following concentration.
Notes: One anionic PRL formulation was concentrated (300 g/L dextran) and then transfected Neuro-2A cells in serum-containing media. GFP expression was observed by 
epifluorescence microscopy 48 hours later. Representative cells are shown in (A) phase contrast and (B) transfected cells appear green (10× magnification).
Abbreviations: GFP, green fluorescent protein; PRL, peptide Y or RVG-9R, siRNA, liposome LaP2.
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Figure 5 Nanocomplexes achieve silencing ex vivo, but not in the brain following intravenous administration.
Notes: Mice brain explants were transfected ex vivo with peptide/siRNA complexes (PR: RVG-9R/BACE1siRNA; 4:1 weight ratio), anionic PEGylated PRL nanocomplexes 
with BACE1 siRNA, L2K, or complexes with irrelevant control siRNA (all at 100 nM), and then 48 hours post-transfection, the tissues were processed for analysis (A) by 
qRT-PCR and (B) by Western blot analysis of the BACE1 protein. Protein silencing was calculated with densitometric analysis using tubulin as loading control. (C) anionic 
PRL nanocomplexes containing RVG-9R and BACE1 siRNA were concentrated using 300 g/L dextran over 3.5 hours, and this concentrated nanoparticle formulation was 
used (D) in intravenous injections. Mice were injected with 100 μl of anionic Prl nanoparticles containing 16 μg or 50 μg Bace1 sirNa or Irr sirNa, and 48 hours later, 
brains were processed for qRT-PCR analysis. The values are the means of three animals ± standard deviation. Asterisks indicate comparisons of specific formulations with 
statistical significance (*P0.05; **P0.01).
Abbreviations: mrNa, messenger rNa; Irr, irrelevant control; sirNa, small interfering rNa; l2K, lipofectamine® 2000; PRL, peptide Y or RVG-9R, siRNA, liposome LaP2; 
RVG, rabies virus glycoprotein targeting peptide; PR, RVG-9R/BACE1siRNA; PEG, polyethylene glycol; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
peptide-containing nanoparticles did not pass the blood–brain 
barrier, as we did not examine their biodistribution.
We then evaluated direct brain administration in rats of 
anionic PRL nanoparticles (with RVG-9R) incorporating 
either BACE1 siRNA or irrelevant control, administered by 
CED38,39 into rat striata, and BACE1 expression was examined 
48 hours later. A significant reduction in BACE1 mRNA 
was observed (Figure 6) between the BACE1-treated group 
and the control groups (P0.05 compared to the irrelevant 
control group; P0.01 compared to the saline group; and 
P0.001 compared to the untreated control group).
Another study also performed direct brain administrations 
rather than using the intravenous route with RVG/siRNA 
complexes, and these showed good brain biodistribution and 
silencing of their target gene.40 The direct method avoids the 
problems of circulation clearance by the first-pass organs 
and the reticuloendothelial system, and requires less siRNA 
compared to the reported 50 μg30,34,35 or 150 μg doses.33 
We have previously shown that anionic nanoparticles 
achieved more widespread dispersal in the brains of rats than 
their cationic counterparts when delivered by CED directly 
into the corpus callosum or striatum15,16 due to their lower 
affinity for anionic cell surface glycoproteins, and have there-
fore explored the potential of anionic siRNA nanocomplexes 
for neurodegenerative diseases. However, with CED, only 
small volumes (~5 μL in rat and ~120 μL in pig brains)41 
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can be delivered in vivo, therefore concentrating the nucleic 
acid-containing nanoparticles is necessary in order to deliver 
higher doses. Further studies using multiple siRNA dosing in 
order to investigate the duration of the silencing effect may 
achieve high levels of silencing for a sustained period using 
systemic or direct administration.
Conclusion
In this study, we described the development of a method 
to concentrate cationic and anionic DNA and siRNA nano-
particles to enhance their utility for in vivo applications. 
Nanoparticles retained their biophysical properties and 
demonstrated similar silencing efficiency and DNA transfec-
tion efficiency in vitro to freshly prepared, nonconcentrated 
nanoparticles, all without cytotoxicity. Direct delivery into 
rat brains of BACE1 siRNA demonstrated significant gene 
silencing. This method of concentrating nanoparticles for 
transfection could be used for other formulations, potentially 
enhancing their utility for in vivo applications.
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animals and n=4 for the saline control animals) with one-way analysis of variance 
and Bonferroni’s post hoc analysis performed to calculate significant differences 
(*P0.05; **P0.01; ***P0.001).
Abbreviations: mrNa, messenger rNa; sirNa, small interfering rNa; ceD, 
convection-enhanced delivery; PEG, polyethylene glycol; PRL, peptide Y or RVG-
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